- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00623090
Internet-Based Education for Prostate Cancer Screening (PCSEd)
December 11, 2012 updated by: Kathryn L. Taylor, Ph.D., Georgetown University
Prostate cancer (PCa) is the leading cancer diagnosis among men and the second leading cause of male cancer death.
However, screening asymptomatic men remains controversial, as early diagnosis and treatment of PCa has not yet demonstrated reduced disease-related mortality in a randomized trial.
The goal of the current study is to develop and assess widely accessible methods to assist men in making informed decisions about PCa screening.
We will compare the efficacy of a new web-based, interactive decision support approach to our existing print-based PCa screening decision tool, among a diverse sample of male primary care patients.
Abundant evidence documents the expanding role of the Internet in increasing access to and understanding of health information and the need for systematic evaluations of Internet-based interventions.
A novel aspect of the proposed trial will be our focus on cognitive biases as a factor that has limited the success of previous information-based interventions.
Specifically, we will evaluate: 1) confirmation bias and 2) short-term consequences bias.
Study Overview
Status
Completed
Conditions
Detailed Description
In Phase I (months 1-8) of this five-year project, we will develop an interactive, Internet-based, patient information and decision aid.
In Phase II (months 9-60), we will evaluate the impact of this decision aid in a randomized controlled trial with male primary care patients aged 45-70 from three Washington, District of Columbia area health care settings (N = 1875).
Trial arms include: 1) print-based information and decision aid (Print), 2) web-based information plus interactive decision aid (Web), and 3) usual care (UC).
Subjects will complete outcome assessments at baseline, one- and 13-months post-baseline.
The specific aims are to: 1. Evaluate the impact of the delivery method (Web vs. Print vs. Usual Care) on the key patient outcome variables of knowledge, decisional satisfaction, and the screening decision.
2. Identify factors that moderate the interventions' impact on the primary outcomes.
3. Identify the mechanisms by which the interventions impact knowledge and decisional satisfaction.
In exploratory analyses, we will evaluate factors that are related to use of the web and print materials.
This research has the potential to make several significant and innovative contributions: 1) the development and evaluation of a widely accessible method of educating a heterogeneous group of patients about a controversial topic, which can be adapted for other similarly contentious issues, 2) a determination of whether Web based materials are a feasible method of patient education for this age cohort, compared to print materials, 3) an understanding of cognitive factors that may hinder comprehension of a controversial medical decision, 4) a determination of who among the target population benefits the most from a web-based intervention, and 5) the information required to streamline and target future web-based educational interventions.
Study Type
Interventional
Enrollment (Actual)
1893
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Washington Hospital Center
-
Washington, District of Columbia, United States, 20007
- Georgetown University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Active primary care patients at Georgetown University Medical Center, Washington Hospital Center, or Medstar Physician Partners (I,e, seen during the past two years)
- English-speaking
- 45-70 years of age; AND
- Ability to provide meaningful consent.
Exclusion Criteria:
- History of prostate cancer.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1 Website
Participants receive the Login information for the Internet we developed on prostate cancer screening.
|
Healthy men between 45-70 receive the login information to access our educational internet site on prostate cancer screening.
|
Active Comparator: 2 Booklet
Participants receive the education booklet we developed on prostate cancer screening.
|
Healthy men between 45-70 receive a copy of our educational print booklet in the mail.
|
Placebo Comparator: 3 Usual Care
Usual care: participants receive no intervention.
|
Healthy men aged 45-70 receive no intervention and are followed for one year, along with the men in the two intervention arms.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
screening decision
Time Frame: one-year follow up
|
one-year follow up
|
knowledge about prostate cancer screening
Time Frame: one-month and one-year post-intervention
|
one-month and one-year post-intervention
|
decisional satisfaction
Time Frame: one-month and one-year post intervention
|
one-month and one-year post intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kathryn L. Taylor, PhD, Georgetown University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2007
Primary Completion (Actual)
March 1, 2011
Study Completion (Actual)
August 1, 2011
Study Registration Dates
First Submitted
February 14, 2008
First Submitted That Met QC Criteria
February 22, 2008
First Posted (Estimate)
February 25, 2008
Study Record Updates
Last Update Posted (Estimate)
December 13, 2012
Last Update Submitted That Met QC Criteria
December 11, 2012
Last Verified
December 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PC051100
- R01CA119168-01 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on educational internet site on prostate cancer screening
-
Centers for Disease Control and PreventionThe University of Texas Health Science Center, HoustonCompletedProstate CancerUnited States
-
Massachusetts General HospitalRecruitingLynch Syndrome | Genetic Predisposition to Disease | Prostate Cancer | BRCA1 Mutation | BRCA2 Mutation | Prostatic Neoplasm | ATM Gene Mutation | MMR MutationUnited States
-
Emory UniversityCompletedProstate CancerUnited States
-
US Department of Veterans AffairsCompleted
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedStage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate CancerUnited States
-
University of Missouri-ColumbiaU.S. Department of EducationCompletedOsteoarthritis | Rheumatoid ArthritisUnited States
-
Tufts UniversityCompletedProstate NeoplasmUnited States
-
Institute of Cancer Research, United KingdomActive, not recruiting
-
Case Comprehensive Cancer CenterCompletedProstate CancerUnited States
-
Centers for Disease Control and PreventionUnknownProstate CancerUnited States